[Personalised medicine in prostate cancer]

Area of Science:

• Oncology
• Genetics

Background:

• Prostate cancer is the most common cancer in men, with incidence increasing with age.
• New treatments offer prolonged survival but increase healthcare costs.
• Individualized treatment requires factors beyond clinical parameters.

Purpose of the Study:

• To review molecular markers for treatment decisions in castration-resistant prostate cancer (CRPCA).
• To highlight the role of advanced diagnostics in understanding tumor dynamics and patient selection.

Main Methods:

• Review of current literature on molecular markers in CRPCA.
• Discussion of diagnostic techniques including liquid biopsies and next-generation sequencing.

Main Results:

• Molecular markers show promise for guiding treatment in CRPCA.
• Genetic analysis of metastatic biopsies provides insights into tumor heterogeneity.
• Liquid biopsies and next-generation sequencing enable better patient selection.

Conclusions:

• Molecular markers are essential for personalized treatment strategies in CRPCA.
• Advanced genomic analyses are key to optimizing therapy and patient outcomes.